Edwards Lifesciences Financial Ratios

Edwards Lifesciences Corporation -- USA Stock  

USD 114.67  1.59  1.41%

Use fundamental data analysis to check all available reported financial drivers of Edwards Lifesciences to find out if markets are presently mispricing the company. We found thirty-five available fundamental indicators for Edwards Lifesciences Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 33.73 times, we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself down the road.Use Edwards Lifesciences to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of Edwards Lifesciences to be traded at $126.14 in 30 days

Edwards Lifesciences Valuation Over Time

Enterprise Value

Edwards Lifesciences Company Summary

Edwards Lifesciences competes with Express Scripts, AmerisourceBergen, Baxter International, and BARD C. It offers transcatheter heart valve therapy solutions comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. Edwards Lifesciences Corp also offer surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue and offer heart valve repair therapies, including annuloplasty rings and systems. Further, Edwards Lifesciences Corp offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings pulmonary artery catheters and continuous venous oximetry catheter for measuring central venous oxygen saturation. Additionally, its critical care solutions include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection and peripheral vascular solutions used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. Edwards Lifesciences Corp distributes its solutions through direct sales force and independent distributors. Edwards Lifesciences Corporationration was founded in 1999 and is headquartered in Irvine, California.

Edwards Lifesciences Retained Earnings vs Total Asset

Edwards Lifesciences Corporation is rated # 5 in retained earnings category among related companies. It is rated below average in total asset category among related companies fabricating about  1.04  of Total Asset per Retained Earnings.

Edwards Lifesciences Fundamentals

    
 Better Than Average     
    
 Worse Than Average Compare Edwards Lifesciences to competition
FundamentalsEdwards LifesciencesPeer Average
Return On Equity26.47 % (15.17) %
Return On Asset13.17 % (15.64) %
Profit Margin22.16 % (5.5) %
Operating Margin29.95 % (10.91) %
Current Valuation22.97 B152.14 B
Shares Outstanding211.16 M1.43 B
Shares Owned by Insiders5.19 % 6.91 %
Number of Shares Shorted1.66 M3.24 M
Price to Earning33.73 times40.69 times
Price to Book7.99 times14.44 times
Price to Sales7.26 times17.81 times
Revenue3.23 B9.85 B
Gross Profit2.17 B21.75 B
EBITDA1.05 B1.41 B
Net Income716.2 M517.71 M
Cash and Equivalents1.13 B3.89 B
Cash per Share5.36 times5.17 times
Total Debt1.02 B7.36 B
Debt to Equity34.5 % 0.72 %
Current Ratio4.06 times3.3 times
Book Value Per Share13.93 times13.64 times
Cash Flow from Operations733 M1.25 B
Short Ratio1.54 times2.09 times
Earnings Per Share3.3 times2.3 times
Price to Earnings To Growth1.75 times1.22 times
Number of Employees9.8 K10.67 K
Beta0.780.34
Market Capitalization23.48 B29.78 B
Total Asset4.06 B126.86 B
Retained Earnings3.91 B38.24 B
Working Capital1.57 B3.58 B
Current Asset2.05 B36.8 B
Current Liabilities476.2 M33.34 B
Z Score13.8708.73
< 1% 

Chance of Financial Distress

Edwards Lifesciences Corporation has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
Details

Growth

Edwards Lifesciences Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth

Compare

Compare Edwards Lifesciences To Peers
Michael Mussallem Chairman and CEO, Ph.D
Catherine Szyman Corporate Vice President Critical Care, MBA
More Executives

Opportunity Range

October 23, 2017 Opportunity Range